podcast.de
Anmeldung
Anmeldung Registrierung
Auto Hell Dunkel
Erweiterte Suche
  1. Startseite
  2. Podcasts
  3. Medizin - Open Access LMU - Teil 15/22 Podcast
  4. Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria
Besides existing artemisinin-based combination therapies,
alternative safe, effective and affordable drug combinations
against falciparum malaria are needed. Methylene blue (MB) was the
first synthetic antimalarial drug ever used, and recent studies
have been promising with regard to its revival in malaria therapy.
The objective of this study was to assess the safety and efficacy
of two MB-based malaria combination therapies, MB-artesunate (AS)
and MB-amodiaquine (AQ), compared to the local standard of care,
AS-AQ, in Burkina Faso. Open-label randomised controlled phase II
study in 180 children aged 6-10 years with uncomplicated falciparum
malaria in Nouna, north-western Burkina Faso. Follow-up was for 28
days and analysis by intention-to-treat. The treatment groups were
similar in baseline characteristics and there was only one loss to
follow-up. No drug-related serious adverse events and no deaths
occurred. MB-containing regimens were associated with mild vomiting
and dysuria. No early treatment failures were observed. Parasite
clearance time differed significantly among groups and was the
shortest with MB-AS. By day 14, the rates of adequate clinical and
parasitological response after PCR-based correction for
recrudescence were 87% for MB-AS, 100% for MB-AQ (p = 0.004), and
100% for AS-AQ (p = 0.003). By day 28, the respective figure was
lowest for MB-AS (62%), intermediate for the standard treatment
AS-AQ (82%; p = 0.015), and highest for MB-AQ (95%; p

Weitere Episoden

Report of the Working Group `Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)'

Report of the Working Group `Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)'

vor 17 Jahren
Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial

Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial

vor 17 Jahren
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

vor 17 Jahren
JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand.

JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand.

vor 17 Jahren
Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis.

Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis.

vor 17 Jahren
Alle Episoden anzeigen
In Podcasts werben
Schalte jetzt Werbung in Podcasts.
Episode melden

„Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria“

Worum geht es? Danach fragen wir noch nach dem Grund.

Abonnenten

Teilen

Mein Archiv

Deine Privatkopie der Folgen, die du nicht verlieren willst.

Podcast-Folgen verschwinden. Feeds werden auf die letzten Episoden gekürzt, Hoster räumen alte Dateien ab, Formate wechseln den Anbieter und lassen ihr Archiv zurück. Mit „Mein Archiv“ sichert podcast.de die Folgen deiner Podcasts für dich — angefangen bei den ältesten, denn die sind zuerst weg.

  • Deine gesicherten Folgen bleiben hörbar, auch wenn das Original offline geht.
  • Auch Folgen, die im heutigen Feed gar nicht mehr stehen — podcast.de kennt sie noch.
  • Herunterladen bleibt möglich, solange die Folge beim Podcaster liegt. Der zählt seine Abrufe wie bisher.
Startet bald

Sei beim Start von Mein Archiv dabei

Mein Archiv ist fast fertig. Trag dich ein, dann bekommst du eine E-Mail, sobald es losgeht – und bist von Anfang an dabei. Wir schreiben dir nur zum Start, keine Werbung, keine Weitergabe deiner Daten.

Du bekommst zuerst eine Bestätigungsmail. Abmelden geht jederzeit. Datenschutz